Across TCGA pan-cancer cohorts, CACNG6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CACNG6 data layer compared with 19 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CACNG6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CACNG6 expression acts as an unfavorable survival marker.
CCRCC and LUAD are the cancer types where CACNG6 mass-spec protein most reproducibly stratifies survival.